The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review
Antonio Pizuorno Machado, Hunter N. Ratliff, Ahmed Afifi, Muhammad H. Vohra, Andrew Kuang, Malek Shatila, Muhammad Ali Khan, Menhaz A. Shafi, Anusha Shirwaikar Thomas, Jessica Philpott, Omar Alhalabi, Yinghong Wang
Abstract
Adverse events from irAE treatment occurred in about one-third of patients that received either steroids or a combination of steroids and other immunosuppressants. Clinicians should be aware of these immunosuppressant-related adverse effects, which can negatively impact cancer treatment and patient outcomes, when treating irAEs and consider shortening treatment duration or using alternative strategies when possible to mitigate these complications, future prospective studies should further investigate the safety of immunosuppressants in treating irAEs.